Skip to content Skip to footer

An Evolving CDMO Landscape

The Evolving Landscape of CDMOs:  A Look at Recent Trends and Future Directions

The Contract Development and Manufacturing Organization (CDMO) sector has been experiencing a significant metamorphosis in recent years. Driven by numerous factors and trends, CDMOs are increasingly evolving to meet the shifting needs of the pharmaceutical and biotech industries. This article explores key trends shaping this industry, as well as the future trajectory of the CDMO sector.

A Shifting Customer Base

One of the most profound shifts in the CDMO landscape is the transformation in the customer base. Traditionally, the primary clientele of CDMOs were large pharmaceutical companies. However, the tide is turning, with smaller biotech firms entering the fray. These companies, primarily focused on developing their drug pipelines, often lack the in-house manufacturing expertise of their larger counterparts. As a result, they seek early integration with partnering CDMOs to aid in their drug development and manufacturing processes, broadening the customer base for CDMOs.

The customer base for CDMOs has experienced a shift from primarily big pharmaceutical companies toward including smaller biotech companies. These smaller companies focus on developing their drug pipelines without having experience in manufacturing and require early integration of their operations with partnering CDMOs in the drug development and manufacturing process.

Isabelle Heiber – Partner, Strategy and Transactions, EY-Parthenon GmbH

The Expansion of the CDMO Value Chain

In response to these changes, three distinct CDMO archetypes are emerging. Firstly, “players at scale” leverage their purchasing power to quickly venture into new areas, and they are typically vastly integrated. Secondly, “extenders” invest heavily in specific segments along adjacent growth trajectories, such as adding fill and finish capabilities to their manufacturing service offerings. Lastly, “complementors” are typically small, highly specialized companies that carefully expand by investing in complementary areas. These archetypes underscore the increasing diversity within the CDMO sector.

The Diversification of CDMO Capabilities

CDMOs are not just evolving in terms of their customer base and business models; their capabilities are also expanding. This expansion occurs along three main axes: within a modality, towards new modalities previously not covered, and from a product-focused approach towards offering additional complementing service categories. This diversification allows CDMOs to better cater to the multifaceted needs of their clients and respond more effectively to market trends and demands.


CDMOs as Technology Innovators

Another exciting development in the CDMO sector is their emerging role as technology innovators. Major companies are increasingly incorporating smaller startups and technology leaders into their ranks. This trend is propelling product-focused companies towards the CDMO service market. With this shift, CDMOs are poised to become formidable contributors to innovation within the pharmaceutical industry. They are expected to gain further relevance through their increasing technological expertise and know-how along the value chain.


Mergers & Acquisitions Activity in the CDMO Sector

In terms of mergers and acquisitions (M&A), the CDMO landscape between 2017 and 2021 has seen an ongoing consolidation trend. CDMOs are focusing their investments on technology and capabilities, reflecting the sector’s shift towards innovation and service expansion. Interestingly, investment firms have become more active in the CDMO sector, indicating a changing investment landscape that recognizes the potential of this evolving market.

In conclusion, the CDMO sector is undergoing a rapid and significant transformation, driven by shifts in customer base, the broadening of the value chain, the emergence of new business models, the expansion of capabilities, and their evolving role as technology innovators. These changes are set against a backdrop of active M&A activity, with a focus on technology and capabilities.

The dynamism in the CDMO sector is clear. As they continue to adapt and evolve, CDMOs will remain a vital cog in the wheel of the pharmaceutical and biotech industries, driving innovation and delivering essential services across the drug development value chain.

As the landscape of the CDMO sector evolves and continues to push the boundaries of innovation, we can expect to see even more exciting developments in the near future. The shift in customer base and the expansion of capabilities are just the tip of the iceberg. As we navigate these changes together, we’d love to hear your thoughts.

What do you think will be the most significant change in the CDMO landscape in the next five years? Are there any trends or innovations that you think will play a pivotal role in shaping the future of this sector?

Join the conversation on Twitter and share your insights with us. You can find us at @bmokabo & @mkbbiopharma. Let’s continue this discussion and explore the possibilities together. #CDMOTrends #InnovationInPharma

Let us know your thoughts, and stay tuned for more insights on the evolving landscape of CDMOs.


Subscribe & Get Updates

Quick Links

Contact Info

Copyright © 2023 MKB Biopharma – All Rights Reserved.